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Abstract
Objective
To address the relationship between novel mutations in polynucleotide 5’-kinase 3’-phos-
phatase (PNKP), DNA strand break repair, and neurologic disease.
Methods
We have employed whole-exome sequencing, Sanger sequencing, and molecular/cellular
biology.
Results
We describe here a patient with microcephaly with early onset seizures (MCSZ) from the Indian
sub-continent harboring 2 novel mutations in PNKP, including a pathogenic mutation in the
fork-head associated domain. In addition, we conﬁrm that MCSZ is associated with hyper-
activation of the single-strand break sensor protein protein poly (ADP-ribose) polymerase 1
(PARP1) following the induction of abortive topoisomerase I activity, a source of DNA strand
breakage associated previously with neurologic disease.
Conclusions
These data expand the spectrum of PNKP mutations associated with MCSZ and show that
PARP1 hyperactivation at unrepaired topoisomerase-induced DNA breaks is a molecular
feature of this disease.
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Mutations in DNA single-strand break repair (SSBR)
proteins are associated with hereditary neurologic
disease.1,2 Recently, using a mouse model in which the
SSBR protein Xrcc1 is mutated, we demonstrated that
hyperactivation of the SSB sensor protein poly(ADP-
ribose) polymerase 1 (PARP1) is a likely source of the
neuropathology induced by SSBs.3 During SSBR, the en-
zyme polynucleotide 59-kinase 39-phosphatase (PNKP)
can employ either DNA 39-phosphatase and/or DNA 59-
kinase activities to restore ligatable termini at DNA strand
breaks, and is recruited to SSBs by interacting with XRCC1
via an amino-terminal fork-head associated (FHA)
domain.4–6 Strikingly, PNKP mutations are associated with
2 apparently distinct neurologic diseases: microcephaly with
early onset seizures (MCSZ) and ataxia with oculomotor
apraxia 4.7,8 The former is a neurodevelopmental disease
associated with developmental delay, microcephaly, and
seizures whereas the latter is a degenerative disease asso-
ciated with cerebellar atrophy, ataxia, and oculomotor
apraxia. Intriguingly, some individuals with PNKP muta-
tions exhibit phenotypic aspects of both disorders, and in
some cases can overlap with Charcot-Marie-Tooth
disease.9,10 To explain the molecular basis and phenotypic
diversity of PNKP-associated disease will require an un-
derstanding of the spectrum of PNKP mutations associated
with disease, and of the inﬂuence of these mutations on
DNA repair. Here, we identify 2 novel disease mutations in
PNKP in a patient with MCSZ from the Indian sub-
continent. We identify a defect in DNA strand break repair
in patient-derived primary ﬁbroblasts and that these MCSZ
cells are associated with hyperactivation of the SSB sensor
protein, PARP1.
Figure 1 Novel PNKP mutations in an individual from India with MCSZ
(A), patientMRI. T2 axial and FLAIR axial images
showing microcephaly with diffuse white mat-
ter signal changes. There is mild ven-
triculomegaly with generalized atrophy and
cystic changes in bilateral temporal lobes.
There is mild hypoplasia of inferior vermis as
seen on sagittal T2 weighted image. (B), Pedi-
gree of the proband (black square). The tri-
angles indicate pregnancies that did not go to
term. Note that one of these (black triangle)
was associated with antenatal detection of
microcephaly. (C), Electropherograms showing
the compound heterozygous PNKP mutations
in the proband and heterozygosity in the
parents. (D), cartoon of PNKP and its functional
domains. The proband mutations, confirmed
by Sanger sequencing, are shown in red. Epit-
opes of the N- and C-terminal polyclonal anti-
bodies used in this study are indicated with
horizontal blue lines. The inset shows the im-
pact of the deletion caused by c.1295_
1298+6del on the splice site between exon 14
and intron 14. FLAIR = fluid-attenuated in-
version recovery; MCSZ = microcephaly with
early onset seizures; PNKP = polynucleotide 59-
kinase 39-phosphatase.
Glossary
CCG = Cologne Center for Genomics; CPT = camptothecin; FHA = fork-head associated; HRP = horseradish peroxidase;
MCSZ = microcephaly with early onset seizures; PARP1 = protein poly (ADP-ribose) polymerase 1; PNKP = polynucleotide 59-
kinase 39-phosphatase; SCAN-1 = spinocerebellar ataxia with axonal neuropathy-1; SSBR = single-strand break repair; WES =
whole-exome sequencing.
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Methods
Patient case report
The patient is currently a 8.5-year-old boy who was born at
term with microcephaly (occipito-frontal circumference 29
cm, –3 SD) and below-normal weight (−2.8 SD). Seizures
began at day 15 of his life and he had severe developmental
delay. He established head control at 6 months and started
sitting with support at month 7, but never attained walking.
He developed monosyllable speech at month 8 but since then
has exhibited a complete developmental arrest. Examination
at;year 8.5 revealed severe microcephaly (−14.9 SD), short
stature (−6.86 SD), and failure to thrive (weight = −5.83SD).
He is a thin child with a slender build, convergent squint,
receding forehead, high nasal bridge, bilateral up slant, re-
ceding chin, dental crowding and teeth caries, spasticity,
brisk reﬂexes, and striatal toe. Ataxia could not be ascer-
tained. He has a cafe´-au-lait spot on his right upper thigh and
dark hyperpigmented skin. He also has a large amplitude
stereotype lower limb movements and midline hand ster-
eotypes. Hearing evaluation revealed an absence of waves at
50 dB in the left ear. At year 4.5, T2 axial and ﬂuid-attenuated
inversion recovery axial MRI images revealed microcephaly
with diﬀuse white matter signal changes (ﬁgure 1A). There
was mild ventriculomegaly with generalized atrophy and
cystic changes in bilateral temporal lobes. Mild hypoplasia of
the inferior vermis was evident on the sagittal T2 weighted
image. His CT scan brain did not show any calciﬁcations.
Figure 2 PNKP protein levels and PNKP activity in MCSZ patient-derived fibroblasts
(A), western blot showing PNKP protein levels in
1BR and PNKP patient fibroblasts after 6 hours
incubation with DMSO vehicle or 10 μM protea-
some inhibitor MG132. Two different antibodies
were employed, directed at the N- or C-terminus
as indicated. p53 and GAPDH detection was
employed as a positive control for proteasome
inhibition by MG132 and as a loading control,
respectively. Asterisks denote nonspecific bands.
(B), PNKP indirect immunofluorescence with the
antibodies described above in 1BR and PNKP
patient fibroblasts. Scale bar 50 μm (C), PNKP
DNA39-phosphatase andDNA59-kinase activity in
wild type 1BR and PNKP patient cell extracts. Top,
A cartoon of the PNKP oligonucleotide duplex
substrate, harboring a SSBwith 39-phosphate and
59-hydroxyl termini. Bottom; reaction products of
PNKP activity. The positions of the substrate (39-P)
and product (39-OH) of PNKP 39-phosphatase ac-
tivity (left panel), and of the substrate (59-OH) and
product (59-P) of the 59-kinase activity (right panel)
are shown. The 40-mer ligation product of the
repair reaction, which is labeled with both TAMRA
and FAM, is indicated by an arrow in the top panel
and is shown in the bottom panels with high
contrast (D), PNKP DNA 39-phosphatase activity in
cell extracts from 1BR and PNKP patient fibro-
blasts additionally transfected with PNKP siRNA.
The 40-mer ligation products are highlighted in
the middle (high contrast) panel. The PNKP
protein levels in the siRNA transfected 1BR and
patient fibroblasts are shown at the bottom.
MCSZ = microcephaly with early onset seizures;
PNKP = polynucleotide 59-kinase 39-phospha-
tase; TAMRA = tetramethylrhodamine.
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EEG at 5 years revealed resolving hypsarryhthmia and
evolving multifocal epilepsy. His karyotype, liver function,
and renal function were all normal. His serum uric acid was
1.2 mg/dL. His serum α fetoprotein levels are 22.9 ng/mL
(normal range 0.89–8.78 ng/mL). His lipid proﬁle showed
mildly high triglycerides 161 (normal range 50–150) with
low density lipoprotein/high density lipoprotein ratio 3.44.
He is at present non-ambulatory, can sit with support, and
does not have seizures.
Whole exome sequencing
Whole-exome sequencing (WES) was performed on DNA
extracted from blood lymphocytes of the index patient
using the SureSelectXT Human All Exon V6 enrichment kit
(Agilent technologies) on an Illumina HiSeq4000 se-
quencer. In total, we obtained a mean coverage of 84 reads,
and 96.3% of target were covered more than 10×. WES data
analysis and variant ﬁltering was conducted using the
exome analysis pipeline “varbank” of the Cologne Center
for Genomics (CCG, varbank.ccg.uni-koeln.de/) and data
were ﬁltered for high-quality (coverage of more than 6
reads, a minimum quality score of 10), rare (minor allele
frequency < 0.5% in the databases of the exome aggregation
consortium and single nucleotide polymorphisms) auto-
somal recessive variants.
Mutation screening
Variants identiﬁed byWES were ampliﬁed fromDNA of the
index patients, and its parents and PCR products were se-
quenced by BigDye Terminator method on an ABI 3500 ×
L Genetic Analyzer (Life Technologies, Germany). Iden-
tiﬁed mutations were re-sequenced in independent
experiments.
Primary human fibroblasts
Control human ﬁbroblast 1BR3 (denoted 1BR in the text)
and PNKP patient-derived skin ﬁbroblasts, obtained with
appropriate patient consent, were grown in minimum essen-
tial media (Gibco) supplemented with 15% fetal bovine se-
rum, 2 mM glutamine, the antibiotics penicillin (100 units/
mL), and streptomycin (100 μg/mL) in a humidiﬁed atmo-
sphere of 5% CO2 at low oxygen (5%) at 37°C.
Figure 3 Elevated levels of TOP1-induced DNA breaks and poly(ADP-ribose) in MCSZ fibroblasts
(A) The accumulation of CPT-induced DNA
strand breaks in 1BR and patient fibro-
blasts, quantified by alkaline comet assays.
Cells were treated with DMSO vehicle or
10 μM CPT for 45 minutes. Data are the
average comet tail moment of 100 cells per
sample and are the mean (±SEM) of 4 in-
dependent experiments. (B) Representative
ScanR images (left) and quantitation (right)
of poly (ADP-ribose) levels in control 1BR
and PNKP patient fibroblasts incubated in
the presence or absence of CPT as above.
Data are themean (±SEM) of 3 independent
experiments. CPT = camptothecin; DMSO =
dimethyl sulphoxide; MCSZ = microcephaly
with early onset seizures; PNKP = poly-
nucleotide 59’-kinase 39’-phosphatase; SEM
= standard error of the mean.
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Antibodies, western blotting, and indirect
immunofluorescence microscopy
Primary antibodies were anti-pan-ADP-ribose binding re-
agent (MABE1016, Millipore), anti-PNKP FHA (SK3195),
anti-PNKP C-terminal (ab18107, Abcam), anti-p53 (OP29,
Millipore), and anti-GAPDH (sc-47724, Santa Cruz). Sec-
ondary antibodies were horseradish peroxidase (HRP)
conjugated goat anti-rabbit (170-6515, Bio-Rad) and goat
anti-mouse (170-6516, Bio-Rad) and for indirect immuno-
ﬂuorescence donkey anti-rabbit Alexa 488 (A21206, Invi-
trogen). For western blotting, cells were lysed in sodium
dodecyl sulphate (SDS) sample buﬀer and subjected to SDS-
PAGE, transferred onto nitrocellulose membrane and
detected by speciﬁc antibodies combined with HRP conju-
gated secondary antibodies. For indirect immunoﬂuores-
cence microscopy, cells were cultured on glass coverslips and
treated where indicated with 10 μM camptothecin (CPT)
(Sigma) for 45 minutes. Cells were ﬁxed with 4% para-
formaldehyde and immunostained as described previously.3
Images were taken using a DMi6000 microscope (Leica)
with 40x dry objective. Automated wide-ﬁeld microscopy
was performed on ScanR system (Olympus) with ScanR
Image Acquisition and Analysis Software, 40x/0.95NA
(UPLSAPO 2 40X) dry objective.
PNKP biochemical activity assays
PNKP substrate was prepared by annealing equimolar amounts
of the ﬂuorophore-labeled deoxyriboligonucleotides (Midland
Certiﬁed Reagent Company) “S1” [5’-(TAMRA)-TAG-
CATCGATCAGTCCTC-39-P], “S2” [59-OH-GAGGTC-
TAGCATCGTTAGTCA-(6-FAM)-3’] and a complementary
strand oligonucleotide [59-TGACTAACGATGCTA-
GACCTCTGAGGACTGATCGATGCTA-3’] in annealing
buﬀer (10 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA).
Cell-free protein extracts were prepared in lysis buﬀer [25 mM
Tris, pH 7.5, 10mMEDTA, 10mMEGTA, 100mMNaCl, 1%
Triton X-100, cOmplete protease inhibitors (Roche)] and in-
cubated (25 μg total protein) with 50 nM substrate and 1 μM
single-stranded nuclease competitor oligonucleotide [59-
AAAGATCACAAGCATAAAGAGACAGG-3’] in reaction
buﬀer (25 mM Tris, pH 7.5, 130 mM KCl, 10 mM MgCl2,
1 mM DTT, 1 mM ATP) at 37°C for 10 minutes in 50 μL
reactions and were terminated by addition of 50 μL quenching
buﬀer (90% formamide, 50mMEDTA, 0.006%Orange G). 10
μL was separated on 20% denaturing polyacrylamide gels and
analyzed on a PharosFX Molecular Imager System (Bio-Rad).
Where indicated, cells were transfected with mix of either
PNKP siRNA #1: 59-CCGGAUAUGUCCACGUGAA-39 and
PNKP siRNA #2: 59-GGAAACGGGUCGCCAUCGA-39 or
non-target siRNA #1: 59-UGGUUUACAUGUCGACUAA-39
and non-target siRNA #2: 59-UGGUUUACAUGUUGU-
GUGA-39) using Lipofectamine RNAiMAX (Life Technolo-
gies) 72 hours before lysis.
Cellular DNA strand break assays
The steady-state level of DNA strand breaks was evaluated by
alkaline comet assays essentially as described11 following
mock-treatment or treatment with 10 μMCPT for 60 minutes
at 37°C. The average comet tail moment in 100 cells per
sample was evaluated by Comet Assay IV software (Percep-
tive Instruments).
Standard protocol approvals, registrations,
and patient consents
Ethical approval and informed parental consent for the use
and publication of patient information and patient derived cell
lines was obtained from the appropriate Institutional and
regional committees. No vertebrate animal models were
employed in this work.
Data availability
Data will be provided on request at https://sussex.ﬁgshare.
com/10.25377/sussex.7836653.
Results
Individuals with neurologic disease resulting from mutations
in PNKP protein have been identiﬁed in the Americas,
Europe, Middle East, and Japan, but surprisingly not yet on
the Indian subcontinent. Here, we describe the ﬁrst Indian
patient with biallelic mutations in PNKP. The proband is an
8.5 year old boy with microcephaly, early-onset seizures, and
developmental delay (MCSZ). Seizures were detected from
day 15 of life and MRI revealed microcephaly with diﬀuse
white matter signal changes and generalized atrophy in the
bilateral temporal lobes (ﬁgure 1A). A detailed case report is
presented in the Methods.
WES on DNA extracted from blood lymphocytes from the
proband identiﬁed 2 heterozygous variants in PNKP (NM_
007254.3); c.63dupC and c.1295_1298+6delCCAGGTAGCG
(ﬁgure 1B and C). Sanger sequencing conﬁrmed the presence of
both mutations in the proband and their heterozygosity in the
parents. c.63dupC is a 1 base pair duplication in exon 2 and was
inherited from the mother, and c.1295_1298+-
6delCCAGGTAGCG is a 10 base pair deletion that was
inherited from the father (ﬁgure 1B and C). The 1 base pair
duplication is predicted to cause a frameshift resulting in
nonsense-mediated mRNA decay and/or truncated PNKP
protein (p.Ile21Hisfs*37) and is the ﬁrst unambiguously dele-
terious mutation identiﬁed in the FHA domain (ﬁgure 1D). The
10 base pair deletion spans the last 4 nucleotides of exon 14 and
the ﬁrst 6 nucleotides of intron 14 (ﬁgure 1C) and deletes
a donor splice-site, leading most likely to nonsense-mediated
mRNA decay and/or a synthesis of a truncated protein.
To deﬁne the consequence of the 2 novel PNKPmutations at
the molecular and cellular level, we employed primary ﬁbro-
blasts established from a skin biopsy from the proband.
Western blotting using antibodies targeting either the
N-terminal or C-terminal regions of PNKP failed to detect
PNKP protein in the patient-derived ﬁbroblasts, even if we
incubated the cells with the proteasome inhibitor MG132 to
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prevent the degradation of the mutant PNKP (ﬁgure 2A).
Incubation with MG132 increased the level of p53 protein,
however, conﬁrming that the proteasome was inhibited in
these experiments. The impact of the 2 novel mutations on
PNKP protein levels was also observed by indirect immuno-
ﬂuorescence, with both N-terminal and C-terminal PNKP
antibodies again detecting little or no PNKP in the patient-
derived ﬁbroblasts (ﬁgure 2B).
Next, we measured the level of PNKP activity using a sensitive
biochemical assay.12 This assay uses an oligonucleotide du-
plex substrate possessing an internal single-nucleotide gap
with 39-phosphate and 59-hydroxyl termini, which is labeled at
the ends of the duplex with the ﬂuorescent dyes tetrame-
thylrhodamine and 6-carboxyﬂuorescein (ﬁgure 2C). The 39-
phosphate and 59-hydroxyl termini in this substrate were
completely repaired by incubation with cell extract from wild
type ﬁbroblasts within 10 minutes. Although greatly reduced,
DNA 39-phosphatase and 59-kinase activities were also
detected in the patient cell extract as indicated by the
formation of a small amount of fully repaired reaction product
(“ligation product”) and also in the case of 39-phosphatase
activity by the appearance of a small amount of
dephosphorylated oligonucleotide (ﬁgure 2C left panel,“39-
OH”). This residual activity in the patient-derived ﬁbroblasts
was greatly reduced or ablated if the patient cells were ﬁrst
transfected with PNKP siRNA, indicating that it reﬂected
residual levels of PNKP (ﬁgure 2D). It is currently unclear
how the residual PNKP activity is generated in the patient
cells, especially with respect to 59-kinase activity, because both
mutations are predicted to result in translational frameshifts
and to truncate either almost all of the protein (in the case of
the maternal allele, c.63dupC) or a large region of the kinase
domain (in the case of the paternal allele, c.1295_1298+6del)
(ﬁgure 1D). Possible explanations include a low level of al-
ternative splicing, an alternative translation start site down-
stream of the premature stop codon in the maternal PNKP
allele, a small amount of properly spliced mRNA arising from
the paternal allele, or the presence of a small amount of an
alternative 59-kinase.
We next examined whether the greatly reduced level of PNKP
protein and activity in the patient cells aﬀected the rate of
DNA strand break repair. DNA strand breaks induced by
abortive topoisomerase 1 (TOP1) activity possess termini
that are substrates for both the DNA kinase and DNA
phosphatase activities of PNKP. Indeed, the PNKP patient
ﬁbroblasts accumulated higher levels of DNA strand breaks
than 1BR control cells during incubation with TOP1 ‘poison’
CPT (ﬁgure 3A). This observation is signiﬁcant, because
defects in the repair of TOP1-induced DNA breaks are also
observed in cells from otherMCSZ patients and from patients
with spinocerebellar ataxia with axonal neuropathy-1 and ataxia
telangiectasia, illustrating their relevance to neurodegenerative
disease13–15. Importantly, hyperactivation of the SSB sensor
protein PARP1 is observed in and is causally linked with
SSBR-defective cerebellar ataxia.3 Consequently, we
wondered whether PARP1 hyperactivation might also be
a feature of these MCSZ cells. Indeed, strikingly, PNKP
patient ﬁbroblasts accumulated much higher levels of the
poly (ADP-ribose) product of PARP1 activity than did
1BR control ﬁbroblasts during treatment with CPT
(ﬁgure 3B).
Our data identify 2 novel PNKP mutations in a patient with
MCSZ from India. Of interest this patient exhibits one of the
most severe forms of MCSZ documented, with a level of
microcephaly and growth retardation comparable to patients
with ataxia telangiectasia and Rad3 related-Seckel Syn-
drome.16 Despite this, in keeping with the functional analysis
of other identiﬁed PNKP mutations,15 cells derived from this
patient retain some residual PNKP activity. This is consistent
with the observation that complete deletion of PNKP in
mouse is embryonic lethal.17 Finally, we have conﬁrmed that
PARP1 hyperactivation is a cellular hallmark of MCSZ cells,
highlighting this phenomenon in the development of a range
of clinically distinct neuro-pathologies.
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